|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11253474||CMP DEV LLC||Pharmaceutical solution of amlodipine||
(18 years from now)
Treatment: Norliqva is indicated for the treatment of hypertension, to lower blood pressure in adults and children 6 years of age and older; norliqva is indicated for the symptomatic treatment of chronic stable angina; norliqva is indicated for the treatment of confirmed or suspected vasospastic angina
|EQ 1MG BASE/ML||SOLUTION;ORAL||Prescription|
Click on the highlighted region to filter.